Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989249 | 0.93 | ACHE (0.41) | ACHEALDH1A1MAPTTSHRLMNA | |
| Hydrochloric Acid SCHEMBL2031981 | 0.88 | ACHE (0.38) | ACHEALDH1A1MAPTTSHRLMNA | |
| Hydrochloric Acid SCHEMBL2031976 | 0.88 | ACHE (0.38) | ACHEALDH1A1MAPTTSHRLMNA | |
| SCHEMBL30477646 | 0.82 | ACHE (0.36) | ACHEALDH1A1MAPTTSHRLMNA | |
| SCHEMBL25060870 | 0.78 | ALDH1A1 (0.37) | ACHEALDH1A1MAPTTSHRLMNA | |
| SCHEMBL12736909 | 0.78 | ALDH1A1 (0.39) | ACHEALDH1A1MAPT | |
| SCHEMBL5680509 | 0.78 | ACHE (0.33) | ACHEALDH1A1MAPT | |
| SCHEMBL6248171 | 0.77 | CYP2A6 (0.44) | ACHEALDH1A1MAPTTSHRLMNA | |
| SCHEMBL2031213 | 0.75 | GABRA1 (0.35) | ALDH1A1TSHRCYP1A2CYP3A4 | |
| SCHEMBL1225139 | 0.75 | ACHE (0.36) | ACHEALDH1A1CYP2A6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637710-B2 | Catalyst for cross-coupling reaction comprising unsubstituted or substituted bisphosphinobenzenes | KYOTO UNIVERSITY (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20110152523-A1 | CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME | KYOTO UNIVERSITY (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152523-A1 | CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME | AHR, AR, HRH2 | ACHE 3316/4885ALDH1A1 2596/4885MAPT 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.